Nonsense. The OC trial was at the behest of interested BPs. That’s why the small trial primary outcome was MOA and not efficacy as measured by tumor reduction. A BP is very likely to partner and run combination trials based on individualized treatment. That has been the target for BP cancer trials for some time, but they lacked a safe and effective p53 drug. Effective, individualized treatment may no longer be science fiction.
Market Data 
Markets 
AI
